Table 4.
Melatonin effective counter-measure for DLaN-evoked grooming behavior.
| Grooming | ||||||
|---|---|---|---|---|---|---|
|
| ||||||
| Cntnap2 KO DLaN vehicle | Cntnap2 KO DLaN melatonin | WT DLaN vehicle | WT DLaN melatonin | Genotype | Treatment | |
| Grooming (sec) | 27.7 ± 2.5 | 11.4 ± 1.6 | 8.4 ± 1.1 | 8.5 ± 1.1 | F = 25.338; P < 0.001 | F = 7.074; P = 0.012 |
| Activity rhythms | ||||||
|
| ||||||
| Cntnap2 KO LD vehicle | Cntnap2 KO DLaN melatonin | WT LD vehicle | WT DLaN melatonin | Genotype | Treatment | |
|
| ||||||
| Power (% variance) | 29.6 ± 2.3 | 40.6 ± 1.9 | 26.2 ± 2.1 | 33.7 ± 1.6 | F = 3.816; P < 0.058 | F = 12.350; P = 0.001 |
| Activity (a.u./24 h) | 2116.1 ± 173.6 | 2075.8 ± 139.4 | 2864.4 ± 249.7 | 4200.4 ± 484.8 | F = 37.432; P < 0.001 | F = 7.614; P = 0.009 |
| Daytime activity (%) | 18.5 ± 1.3 | 12.7 ± 1.4 | 16.2 ± 1.6 | 11.7 ± 0.8 | F = 0.939; P = 0.338 | F = 9.649; P = 0.003 |
| Onset Variability (min) | 30.1 ± 3.9 | 12.8 ± 2.0 | 43.3 ± 1.8 | 36.7 ± 3.8 | F = 15.366; P < 0.001 | F = 9.099; P = 0.005 |
| Fragmentation | 11.8 ± 0.4 | 10.7 ± 0.5 | 8.6 ± 0.5 | 9.4 ± 0.6 | F = 14.213; P < 0.001 | F = 0.089; P = 0.763 |
Two-way ANOVA followed by Holm-Sidak’s multiple comparisons test was used to evaluate the effects of genotype and treatment. Data are reported as the mean ± SEM. P values < 0.05 were considered significant and are shown in bold.